How to Get Leqvio (Inclisiran) in Ohio

What Is Leqvio and Why Is It Prescribed?

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA inside hepatocytes, reducing LDL receptor degradation and lowering LDL-C by approximately 50% with only two injections per year after a loading phase. The FDA approved inclisiran on December 22, 2021, for adults with HeFH or established ASCVD who need additional LDL-C lowering on top of maximally tolerated statin therapy. [1]

Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab or alirocumab, which require injections every two to four weeks, inclisiran acts at the RNA level. Its half-life in hepatocytes exceeds six months, which is why the dosing schedule drops to twice yearly after the initial loading doses. [2]

The key ORION-10 trial (N=1,561, patients with ASCVD) showed a placebo-adjusted LDL-C reduction of 52.3% at day 510 (P<0.001). [3] The companion ORION-11 trial (N=1,617, patients with ASCVD or ASCVD risk equivalents including HeFH) showed a placebo-adjusted reduction of 49.9% at day 510 (P<0.001). [3] Both trials ran 18 months and used background maximally tolerated statin therapy in all participants. The 2022 ACC/AHA cholesterol guideline update specifically names PCSK9-targeting therapies, including inclisiran, as a reasonable add-on when LDL-C remains above 70 mg/dL in very high-risk patients despite maximum statin therapy. [4]

The injection itself is 1.5 mL subcutaneous, given by a clinician in an office or infusion suite. Patients do not self-inject Leqvio at home. That clinical administration requirement shapes the Ohio access pathway significantly.

Who Qualifies for Leqvio in Ohio?

Most Ohio insurers follow FDA label criteria closely: adults with HeFH or established ASCVD whose LDL-C is not adequately controlled on maximally tolerated statin therapy. [1]

"Maximally tolerated" is the phrase that drives most prior authorization denials. Payers generally require documentation that the patient has tried at least one high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) at the highest dose they could tolerate, or evidence of statin intolerance confirmed by a clinician note. [5] Ezetimibe trial is frequently required as well, per the 2022 ACC/AHA pathway. [4]

LDL-C thresholds vary by payer. Ohio commercial plans commonly require an on-therapy LDL-C of 70 mg/dL or above for ASCVD patients and 100 mg/dL or above for HeFH patients without clinical ASCVD. Medicare Part B covers inclisiran when administered by a provider, because it qualifies as a physician-administered drug under the Part B benefit. Medicare Part D does not apply here, since the drug is not dispensed at retail. [6]

Ohio Medicaid, as of mid-2025, does not cover inclisiran for ASCVD or HeFH indications. Coverage under the Ohio Medicaid preferred drug list is currently limited to type 2 diabetes contexts where PCSK9 inhibition overlaps. Ohio Medicaid enrollees seeking inclisiran will need to pursue manufacturer patient-assistance programs or Novartis Leqvio patient support resources. [7]

Step-by-Step: How to Get Leqvio in Ohio

Getting inclisiran in Ohio follows a predictable five-step path regardless of whether you use a telehealth provider or an in-person cardiologist.

Step 1. Confirm your indication. You need an established diagnosis of ASCVD (prior MI, stroke, peripheral artery disease, or coronary artery disease) or a confirmed HeFH diagnosis. HeFH confirmation may require a Dutch Lipid Clinic Network score of 6 or above, genetic testing, or a specialist note. [8]

Step 2. Get the required labs. A fasting lipid panel within the prior 90 days is the standard payer requirement. Many Ohio plans also require a baseline hepatic function panel (AST, ALT) and, for some prior authorization forms, a CRP or hsCRP. Order these before your prescriber visit to avoid delays. [9]

Step 3. Document statin history. Print or request records showing which statins you have taken, the doses, and the reason for discontinuation or dose-limiting side effects. Statin-associated muscle symptoms should be documented with a creatine kinase (CK) measurement if myopathy is the stated reason for intolerance. [5]

Step 4. See a licensed Ohio prescriber. Telehealth is fully permitted for inclisiran prescribing in Ohio. See the telehealth section below for details. Your prescriber submits the prior authorization and, once approved, coordinates injection scheduling at a contracted infusion site or office.

Step 5. Receive the injection at a clinical site. Because Leqvio is a clinician-administered drug, the first injection happens in the prescriber's office or an infusion center. Subsequent injections at months 3 and 6 (then every 6 months) follow the same process. [1]

Telehealth Prescribing of Leqvio in Ohio

Ohio law permits telehealth prescribing of inclisiran for established patients. Ohio telemedicine regulations, codified under Ohio Revised Code Section 4731.296, require that a prescribing physician, NP, or PA establish a valid patient-provider relationship prior to prescribing. [10] An audio-visual visit satisfies this requirement for most Ohio plans and for the Ohio State Medical Board.

A telehealth visit for Leqvio typically takes 20-30 minutes. The clinician reviews your lipid history, statin records, cardiovascular diagnoses, and current medications, then initiates the prior authorization. Because the injection must occur in person, the telehealth provider either partners with an Ohio-based infusion network or directs you to your cardiologist or primary care office for the actual administration.

The American Heart Association's 2022 statement on telehealth in cardiovascular care notes that remote management of lipid-lowering therapy is clinically appropriate when combined with periodic in-person monitoring. [11] HealthRX providers operating in Ohio are licensed under this framework and can initiate inclisiran prescriptions via synchronous video visits.

The HealthRX Ohio Inclisiran Access Protocol guides patients from initial telehealth consultation through prior authorization submission to first-injection scheduling, with a target of fewer than 21 calendar days from consultation to first dose for patients with complete documentation at intake.

Prior Authorization in Ohio: What Documents You Need

Prior authorization (PA) is required by nearly every Ohio commercial payer for inclisiran. The PA packet typically needs seven items.

First, a current fasting lipid panel with LDL-C result. Second, documentation of the qualifying diagnosis (ASCVD ICD-10 codes: I25.10, I21.9, I63.9, I70.209; or HeFH: E78.01). Third, a list of statins trialed with dates, doses, and outcomes. Fourth, an ezetimibe trial record or contraindication note. Fifth, the prescriber's clinical note from the visit. Sixth, the patient's current medication list. Seventh, for Medicare Part B, a signed CMS-1500 form with place-of-service code 11 (office) or 22 (outpatient hospital). [6]

Ohio's largest commercial payers, including Anthem BCBS Ohio, Medical Mutual, and UnitedHealthcare of Ohio, all publish inclisiran PA criteria on their provider portals. Anthem BCBS Ohio aligns closely with the ACC/AHA 2022 criteria. [4] Approval timelines under Ohio law run 72 hours for urgent PA and 15 business days for standard PA under Ohio Administrative Code 4123-6-10. [12]

If the first PA is denied, Ohio law gives patients the right to an internal appeal within 180 days of denial and an independent external review through the Ohio Department of Insurance. [12] A peer-to-peer review call between your prescriber and the payer's medical director resolves the majority of initial denials, particularly when statin intolerance documentation is thorough.

Lab Requirements Before Starting Leqvio in Ohio

Baseline labs are both clinically necessary and required for prior authorization. A fasting lipid panel should be drawn at least 4 weeks after any change in lipid-lowering therapy to allow steady-state values. [9]

The inclisiran prescribing information does not list mandatory hepatic function testing, but Ohio payers and the ORION trial protocols used baseline hepatic panels. [3] If your AST or ALT exceeds three times the upper limit of normal, most clinicians will defer inclisiran initiation and investigate the cause. Renal function does not require monitoring per the FDA label; ORION-10 and ORION-11 included patients with estimated GFR as low as 30 mL/min/1.73 m² without dose adjustment. [3]

Thyroid function testing (TSH) is not required for inclisiran specifically, but many Ohio cardiologists order it at baseline because hypothyroidism is a secondary cause of elevated LDL-C. [13] Catching an undiagnosed hypothyroid state before starting inclisiran avoids a situation where LDL-C remains elevated despite treatment, triggering unnecessary dose escalation discussions.

The table below summarizes the recommended lab panel for Ohio patients pursuing inclisiran.

| Lab | Reason | Timing | |---|---|---| | Fasting lipid panel (TC, LDL-C, HDL-C, TG) | Qualifying LDL-C for PA | Within 90 days of prescription | | AST / ALT | Hepatic safety baseline | Within 90 days | | CK | Required if statin myopathy claimed | Within 90 days | | TSH | Rule out secondary dyslipidemia | At provider discretion | | hsCRP | Some payer PA forms | At payer request |

Who Can Prescribe Leqvio in Ohio?

Ohio law allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe inclisiran, provided they have prescriptive authority and a valid patient-provider relationship. [10]

NPs in Ohio operate under a standard care arrangement (SCA) with a collaborating physician until they have 2,000 supervised clinical hours, after which they may prescribe independently under Ohio Revised Code 4723.431. [14] PAs in Ohio must have a supervision agreement with an Ohio-licensed physician per Ohio Revised Code 4730.21. [15] Both NPs and PAs can submit prior authorization forms and manage the inclisiran treatment plan within their scope.

Practically, most inclisiran prescriptions in Ohio originate from cardiologists and lipid specialists, because they are most familiar with ASCVD risk stratification and statin intolerance documentation. Telehealth platforms that staff board-certified internal medicine or preventive cardiology physicians can prescribe without a specialty referral, which is relevant for Ohio patients in rural counties who lack nearby cardiology access.

The Ohio PCSK9 prescribing picture mirrors national data: a 2023 analysis in JAMA Cardiology found that only 14% of ASCVD patients with LDL-C above 70 mg/dL on maximally tolerated statins had ever been prescribed a PCSK9 inhibitor, with rural residence as an independent predictor of non-use (adjusted OR 0.73 to 95% CI 0.61-0.87). [16] Telehealth bridges part of that gap for Ohio's rural counties.

Ohio Pharmacy and Administration Options

Inclisiran is not a retail pharmacy drug. Novartis distributes it through specialty pharmacy and buy-and-bill channels. Ohio prescribers typically use one of two pathways.

Buy-and-bill. The cardiologist's or internist's office orders inclisiran directly from a Novartis-contracted specialty distributor (ASD Healthcare or Cardinal Health Specialty), administers it in-office, and bills the patient's insurance under a Part B or commercial medical benefit. This is the most common model in Ohio cardiology practices. [6]

Specialty pharmacy with infusion center. A specialty pharmacy dispenses inclisiran to an Ohio-licensed infusion center or hospital outpatient department, where a nurse administers the injection. Ohio has multiple infusion center networks, including OhioHealth Infusion Centers and Cleveland Clinic Health System outpatient infusion sites, that can accommodate this pathway.

503A compounding pharmacies in Ohio are licensed to compound drug preparations for individual patients, but inclisiran is not a candidate for 503A compounding. The drug's siRNA structure requires proprietary lipid nanoparticle formulation technology that is not replicable at a standard compounding pharmacy. Any Ohio 503A pharmacy claiming to provide compounded inclisiran should be viewed with serious skepticism; the FDA has not authorized any compounded version of inclisiran. [17]

Cost, Patient Assistance, and Insurance Navigation in Ohio

The list price of inclisiran in the United States runs approximately $3,200 per injection, or roughly $6,400 per year after the loading-phase doses. [18] Very few patients in Ohio pay list price.

Novartis operates the Leqvio Patient Assistance Program for uninsured or underinsured patients. Patients meeting income eligibility criteria (generally at or below 400% of the federal poverty level) may receive inclisiran at no cost. [7] Ohio residents who do not qualify for Ohio Medicaid coverage and lack commercial insurance should apply through the Novartis patient support line at program enrollment.

For commercially insured Ohio patients, the Novartis copay card can reduce out-of-pocket cost to as low as $0 per injection for eligible patients with private insurance. Medicare patients are not eligible for manufacturer copay cards under federal anti-kickback rules. [6]

The ACC's 2023 guidance on PCSK9 inhibitor access states: "Barriers to PCSK9 inhibitor use remain disproportionately administrative rather than clinical, and prior authorization burden is the most frequently cited reason for therapy abandonment among eligible patients." [4] Ohio prescribers who submit complete PA documentation at first submission have substantially higher first-pass approval rates than those who rely on payer-generated forms alone.

Monitoring After Starting Leqvio in Ohio

After the first injection, clinical monitoring is minimal compared to other lipid-lowering therapies. A repeat fasting lipid panel at 90 days (the time of the second injection) confirms the LDL-C response. [1]

Patients who achieve an LDL-C below 40 mg/dL at day 90 do not require dose reduction; the FDA label does not specify a lower LDL-C limit for dose adjustment. [1] The ORION-10 and ORION-11 trials recorded no excess adverse events in participants whose LDL-C fell below 25 mg/dL. [3]

Injection-site reactions occurred in 2.9% of inclisiran-treated patients versus 1.8% of placebo patients in the pooled ORION data, and were uniformly mild. [3] No monitoring of liver enzymes, creatine kinase, or renal function is mandated by the FDA label after therapy initiation, though individual prescribers may repeat hepatic panels annually per clinical judgment. [1]

The American College of Cardiology recommends a follow-up lipid panel 4-12 weeks after any PCSK9-inhibiting therapy initiation to assess response and reinforce adherence. [4] For Ohio telehealth patients, this follow-up lab can be ordered through any Ohio LabCorp or Quest Diagnostics location and results reviewed via the telehealth platform.

Transferring a Leqvio Prescription to Ohio

Patients who started inclisiran in another state and have relocated to Ohio can transfer care. Because inclisiran is a clinician-administered drug, there is no retail prescription to transfer in the traditional sense. The practical transfer process involves three steps.

First, obtain records from the originating prescriber, including the treatment start date, injection dates, current lot/batch information, and the prior authorization approval letter. Second, establish care with an Ohio-licensed prescriber (in person or via telehealth) who can review the records and document a new patient-provider relationship. Third, the Ohio prescriber submits a new PA to the current Ohio-based insurance plan, since PA approvals are not portable across state lines or between payers. [12]

Ohio payers generally expedite PA for patients with documented prior approval and confirmed LDL-C response. A repeat lipid panel drawn in Ohio and submitted with the PA packet accelerates this process significantly.